
    
      Tenalisib is a highly specific and orally available dual PI3K δ/γ inhibitor. Pre-clinical
      experiments demonstrated that Tenalisib is highly effective in killing primary CLL cells in
      vitro. A Phase II study is planned to evaluate the efficacy and safety of Tenalisib in
      patients with relapsed/refractory CLL.
    
  